Since 2002, Novozymes has relied on the GRI framework to guide its integrated reporting. We have followed the developments in the GRI Standards (previously known as GRI Guidelines) over the years and use them as a yardstick to measure our sustainability performance.
Reporting specifications
Novozymes refers to GRI Standard 101: Foundation 2016 to inspire its materiality assessment process. Our material issues have been identified through a robust assessment process and mapped with relevant GRI Categories and Disclosures.
We refer to GRI 102: General Standard Disclosures 2016 to provide information on organizational profile, strategy, ethics and integrity, governance, stakeholder engagement and reporting practices. This information is reported throughout The Novozymes Report 2018 under relevant report sections.
The GRI 103: Management Approach 2016 guides our reporting on the management approach to material issues. Our disclosure on material issues is contained in the Accounts and performance section of The Novozymes Report 2018. The disclosure on management approach includes information on four aspects:
Furthermore, we have reported topic-specific disclosures for each of the material issues identified under Economic, Environmental and Social categories by referring to the GRI 200 Economic Standard, GRI 300 Environmental Standard and GRI 400 Social Standard respectively.
The GRI Index provided here serves as a guide to where you can find more detailed information on general and topic-specific information reported throughout The Novozymes Report 2018.
The material issues have been mapped against their relevant GRI Categories and Disclosures to link Novozymes’ material issues to the nomenclature used by GRI.
Material Issues | GRI Category (ies) | Disclosure |
Innovation | Economic | GRI 201: Economic Performance; GRI 203: Significant Indirect Economic Impact |
Profitable growth | Economic | GRI 201: Economic Performance |
Partnerships & customer engagement | Economic and Social | GRI 201: Economic Performance; GRI 416: Customer Health and Safety |
Compliance | Economic and Social | GRI 307: Environmental Compliance; GRI 419: Socioeconomic Compliance |
Climate change & energy | Environmental | GRI 305: Emissions; GRI 302: Energy |
Business ethics | General disclosure and Economic | GRI 102-16 to 102-17: Ethics and Integrity; GRI 205: Anti-Corruption; GRI 206: Anti-Competitive Behavior |
Corporate governance | General disclosure and Economic | GRI 102-18 to 102-39: Governance; GRI 405: Diversity and Equal Opportunity |
Water | Environmental | GRI 303: Water and Effluents |
Product stewardship | Social | GRI 416: Customer Health and Safety; GRI 417: Marketing and Labeling |
Solid capital structure | Economic | GRI 201: Economic Performance |
Trade policies | Economic | GRI 201-1: Direct Economic Value Generated and Distributed |
Bioethics & biodiversity | Environmental | - |
Occupational health & safety | Social | GRI 403: Occupational Health & Safety |
Community engagement & social investment | Economic and Social | GRI 413: Local Communities; GRI 203: Significant Indirect Economic Impact |
Responsible sourcing | Environmental and Social | GRI 308: Supplier Environmental Assessment; GRI 414: Supplier Social Assessment |
Labor practices & human rights | Social | GRI 401: Employment; GRI 402: Labor Management Relations; GRI 404: Training and Education; GRI 405: Diversity and Equal Opportunity; GRI 407: Freedom of Association and Collective Bargaining; GRI 408: Child Labor; GRI 409: Forced or Compulsory Labor; GRI 414: Supplier Social Assessment; GRI 412: Human Rights Assessment |
Waste | Environmental | GRI 306: Effluents and Waste |
Data security | Economic and Social | GRI 102-29 to 30: Governance |
Tax | Economic | GRI 201: Economic Performance |
Animal welfare | Environmental | GRI 307: Environmental Compliance |
Deforestation & land use change | Environmental | - |
GRI disclosure | References and comments | Reporting extent | |
102-14 | Statement from senior decision-maker | Letter from the CEO: Building sustainable growth during times of rapid change in The Novozymes Report 2018 | Full |
CEO statement of continued commitment: Innovating for a sustainable tomorrow in the Sustainability section of The Novozymes Report 2018 | |||
102-15 | Key impacts, risks and opportunities | Risk management in The Novozymes Report 2018 | Full |
Business model in The Novozymes Report 2018 | |||
Notes 7.1 to 8.6 in The Novozymes Report 2018 | |||
102-16 | Values, principles, standards and norms of behavior | About us on Novozymes.com | Full |
Touch the world on Novozymes.com | |||
Position paper on Business integrity on Novozymes.com | |||
Note 8.3 Business ethics in The Novozymes Report 2018 | |||
102-17 | Mechanisms for advice and concerns about ethics | Position paper on Business integrity on Novozymes.com | Full |
Contact us: Novozymes' Whistleblower System on Novozymes.com | |||
Note 8.3 Business ethics in The Novozymes Report 2018 |
GRI disclosure | References and comments | Reporting extent | |
102-40 | List of stakeholder groups | Better together on Novozymes.com | Full |
Engagement in the Sustainability section of The Novozymes Report 2018 | |||
102-41 | Collective bargaining agreements | Novozymes does not report publicly on this information | Not reported |
Novozymes supports employees' rights to join associations and bargain collectively, but we do not register employees' memberships of unions, since this is illegal in several of the countries in which we operate | |||
102-42 | Identifying and selecting stakeholders | Stakeholder engagement occurs across various functions and departments of Novozymes. We do not publicly disclose our basis for identifying and selecting stakeholders to engage with | Partial |
Communication Policy in Positions & Policies on Novozymes.com | |||
Engagement in the Sustainability section of The Novozymes Report 2018 | |||
Materiality in Note 1 Basis of reporting in The Novozymes Report 2018 | |||
102-43 | Approach to stakeholder engagement | Materiality in Note 1 Basis of reporting in The Novozymes Report 2018 for information specific to stakeholder engagement in the materiality assessment process | Partial |
With the exception of stakeholder engagement in the materiality assessment process, we do not report frequency of engagement by type and stakeholder group as this is a continuous process | |||
Engagement in the Sustainability section of The Novozymes Report 2018 | |||
Communication Policy in Positions & Policies on Novozymes.com | |||
102-44 | Key topics and concerns raised | Materiality in Note 1 Basis of reporting in The Novozymes Report 2018 | Partial |
Engagement in the Sustainability section of The Novozymes Report 2018 | |||
GRI disclosure | References and comments | Reporting extent | |
GRI 302: Energy | |||
103 | Management approach disclosures | Note 7.2 Energy in The Novozymes Report 2018 | Full |
302-1 | Energy consumption within the organization | Note 7.2 Energy in The Novozymes Report 2018 | Full |
302-4 | Reduction in energy consumption | Environmental data in The Novozymes Report 2018 | Partial |
Note 7.2 Energy in The Novozymes Report 2018 | |||
GRI 303: Water and Effluents 2018 | |||
103 | Management approach disclosures | Note 7.3 Water in The Novozymes Report 2018 | Full |
303-1 | Interactions with water as a shared resource | Novozymes reports water withdrawal by type (such as drinking water, industrial water and steam), but does not disclose withdrawal by source | Partial |
303-3 | Water withdrawal | Note 7.3 Water in The Novozymes Report 2018 | Partial |
303-4 | Water discharge | Note 7.3 Water in The Novozymes Report 2018 | Partial |
GRI 305: Emissions | |||
103 | Management approach disclosures | Note 7.1 Climate change in The Novozymes Report 2018 | Full |
305-1 | Direct (Scope 1) GHG emissions | Note 7.1 Climate change in The Novozymes Report 2018 | Full |
Our disclosure on emissions adheres to Novozymes' accounting policies and follows an operational control approach | |||
Novozymes’ disclosure on biogenic emissions can be found in our response to the CDP Investor questionnaire on www.cdp.net | |||
305-2 | Energy indirect (Scope 2) GHG emissions | Note 7.1 Climate change in The Novozymes Report 2018 | Full |
Our disclosure on emissions adheres to Novozymes' accounting policies and follows an operational control approach | |||
305-3 | Other indirect (Scope 3) GHG emissions | Note 7.1 Climate change in The Novozymes Report 2018 | Partial |
GRI 306: Effluents and Waste | |||
103 | Management approach disclosures | Note 7.3 Water in The Novozymes Report 2018 | Full |
Note 7.4 Waste in The Novozymes Report 2018 | |||
306-1 | Total water discharge by quality and destination | Novozymes does not report on the quality of the water or the treatment methods, because different sites apply different treatment methods and measures based on local requirements | Partial |
Note 7.3 Water in The Novozymes Report 2018 | |||
306-2 | Waste by type and disposal method | Environmental performance in The Novozymes Report 2018 | Full |
Note 7.4 Waste in The Novozymes Report 2018 | |||
The waste disposal method is site specific and determined in line with local requirements | |||
306-3 | Significant spills | There were no significant spills in 2018 | Full |
GRI 307: Environmental Compliance | |||
103 | Management approach disclosures | Note 7.5 Environmental compliance, etc. in The Novozymes Report 2018 | Full |
307-1 | Non-compliance with environmental laws and regulations | Novozymes did not receive any significant fines or nonmonetary sanctions related to noncompliance with environmental laws and regulations in 2018 | Full |
Environmental performance in The Novozymes Report 2018 | |||
Note 7.5 Environmental compliance, etc. in The Novozymes Report 2018 | |||
GRI 308: Supplier Environmental Assessment | |||
103 | Management approach disclosures | Note 8.6 Responsible sourcing in The Novozymes Report 2018 | Full |
308-1 | New suppliers that were screened using environmental criteria | Note 8.6 Responsible sourcing in The Novozymes Report 2018 | Partial |
GRI disclosure | References and comments | Reporting extent | |
GRI 401: Employment | |||
103 | Management approach disclosures | Note 8.1 Labor practices & human rights in The Novozymes Report 2018 | Full |
401-1 | New employee hires and employee turnover | Note 8.1 Labor practices & human rights and Note 2.3 Employees in The Novozymes Report 2018 | Partial |
Social and governance performance in The Novozymes Report 2018 | |||
Site data in The Novozymes Report 2018 | |||
401-2 | Benefits provided to full-time employees that are not provided to temporary or part-time employees | Employee benefits, including life insurance, healthcare, disability/invalidity coverage, maternity/paternity leave, retirement provision and others are provided to full-time employees of Novozymes as a minimum, as required by law. Temporary and part-time employees (including interns) are entitled to a number of employee benefits, as per the national regulations and industry standards of the regions in which we operate | Full |
GRI 403: Occupational Health and Safety 2018 | |||
103 | Management approach disclosures | Note 8.2 Occupational health & safety in The Novozymes Report 2018 | Full |
403-1 | Occupational health and safety management system | Note 8.2 Occupational health & safety in The Novozymes Report 2018 | Full |
403-2 | Hazard identification, risk assessment, and incident investigation | Note 8.2 Occupational health & safety in The Novozymes Report 2018 | Partial |
403-3 | Occupational health services | Note 8.2 Occupational health & safety in The Novozymes Report 2018 | Partial |
403-7 | Prevention and mitigation of occupational health and safety impacts directly linked by business relationships | Note 8.2 Occupational health & safety in The Novozymes Report 2018 | Partial |
403-9 | Work-related injuries | Note 8.2 Occupational health & safety in The Novozymes Report 2018 | Partial |
Site data in the Novozymes Report 2018 | |||
403-10 | Work-related ill health | Note 8.2 Occupational health & safety in The Novozymes Report 2018 | Partial |
Site data in The Novozymes Report 2018 | |||
GRI 404: Training and Education | |||
103 | Management approach disclosures | Note 8.1 Labor practices & human rights in The Novozymes Report 2018 | Full |
404-2 | Programs for upgrading employee skills and transition assistance programs | Targets: ENABLE in The Novozymes Report 2018 | Partial |
Note 8.1 Labor practices & human rights in The Novozymes Report 2018 | |||
GRI 405: Diversity and Equal Opportunity | |||
103 | Management approach disclosures | Note 8.1 Labor practices & human rights in The Novozymes Report 2018 | Full |
405-1 | Diversity of governance bodies and employees | Novozymes reports on percentage employees by job category, but not on minority groups because registration of ethnic origin is illegal in many of the regions in which we operate | Partial |
Competency profile of the Board of Directors at investors.novozymes.com | |||
Note 2.3 Employees in The Novozymes Report 2018 | |||
Target: ENABLE in The Novozymes Report 2018 | |||
Corporate governance in The Novozymes Report 2018 | |||
GRI 407: Freedom of Association and Collective Bargaining | |||
407-1 | Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk | Novozymes recognizes the right to organize and negotiate. This has led to various arrangements in countries where this right is not recognized in local legislation. Novozymes supports employees’ rights to join associations and bargain collectively, but we do not register employees’ memberships of unions, since this is illegal in several of the countries in which we operate | Partial |
Position paper on Human rights and labor standards on Novozymes.com | |||
Note 8.1 Labor practices & human rights in The Novozymes Report 2018 | |||
GRI 408: Child Labor | |||
103 | Management approach disclosures | Note 8.1 Labor practices & human rights in The Novozymes Report 2018 | Full |
408-1 | Operations and suppliers identified at significant risk for incidents of child labor | Position paper on Human rights and labor standards on Novozymes.com | Partial |
Note 8.1 Labor practices & human rights in The Novozymes Report 2018 | |||
GRI 409: Forced and Compulsory Labor | |||
103 | Management approach disclosures | Note 8.1 Labor practices & human rights in The Novozymes Report 2018 | Full |
409-1 | Operations and suppliers identified at significant risk for incidents of forced or compulsory labor | Position paper on Human rights and labor standards on Novozymes.com | Partial |
Note 8.1 Labor practices & human rights in The Novozymes Report 2018 | |||
GRI 412: Human Rights Assessments | |||
103 | Management approach disclosures | Note 8.1 Labor practices & human rights in The Novozymes Report 2018 | Full |
412-1 | Total number and percentage of operations that have been subject to human rights reviews or human rights impact assessments, by country. | Note 8.1 Labor practices & human rights in The Novozymes Report 2018 | Full |
GRI 413: Local Communities | |||
103 | Management approach disclosures | Note 8.4 Community engagement in The Novozymes Report 2018 | Full |
413-1 | Operations with local community engagement, impact assessments and development programs | We have programs focused on education and are implemented with local communities in regions of significant operations. | Partial |
Note 8.4 Community engagement in The Novozymes Report 2018 | |||
ESG integration on Novozymes.com | |||
Strategic social investment in the Sustainability section of The Novozymes Report 2018 | |||
GRI 414: Supplier Social Assessment | |||
103 | Management approach disclosures | Note 8.6 Responsible sourcing in The Novozymes Report 2018 | Full |
414-1 | New suppliers that were screened using social criteria | Note 8.6 Responsible sourcing in The Novozymes Report 2018 | Partial |
Position paper on responsible purchasing on Novozymes.com | |||
GRI 416: Customer Health and Safety | |||
103 | Management approach disclosures | Note 7.7 Product stewardship in The Novozymes Report 2018 | Full |
416-1 | Assessment of health and safety impacts of products and services | 100% of our significant product and service categories are assessed for health and safety impacts | Full |
Novozymes’ Quality and Product Safety Policy on Novozymes.com | |||
Enzymes and safety on Novozymes.com | |||
Safety material on Novozymes TV | |||
GRI 417: Maketing and Labeling | |||
103 | Management approach disclosures | Note 7.7 Product stewardship in The Novozymes Report 2018 | Full |
417-1 | Requirements for product and service information and labeling | 100% of our significant product and service categories are covered by and assessed for compliance with labeling and regulatory requirements | Full |
Regulatory compliance on Novozymes.com |